Safety Follow-up Study of Cellgram-ED in Post-Radical Prostatectomy Erectile Dysfunction

NCT07431008 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2026-02-24

No results posted yet for this study

Summary

This phase II clinical trial with safety follow-up is designed to evaluate the efficacy and safety of Cellgram-ED (autologous bone marrow-derived mesenchymal stem cells) administered via intracavernous injection in patients with erectile dysfunction after radical prostatectomy.

Conditions

Sponsors & Collaborators

  • Pharmicell Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Bumjin Lim, Ph.D · AIDS Malignancy Consortium

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-26
Primary Completion
2030-01-10
Completion
2030-01-10

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07431008 on ClinicalTrials.gov